Company: BriaCell Therapeutics Corp.

Form Type: 10-Q

Filing Date: 2024-12-16

Corporate Action: Spin-off

Type: Update

Accession Number: 000149315224050214

Comments: BriaCell Therapeutics Corp. filed its Form 10-Q for the quarterly period ended October 31, 2024. The report indicates a significant ongoing commitment to its clinical programs, particularly the Bria-IMT targeted immunotherapy program, which is in a pivotal Phase 3 study approved by the FDA for advanced breast cancer. The overall financial performance shows a net loss of $5,829,276 for the quarter compared to a net income of $5,958,872 in the same quarter of the previous year. Key highlights include a reduction in research and development expenses to $3,665,341, a decrease driven by lower clinical trial costs. Additionally, the document discusses a spin-out transaction that occurred on August 31, 2023, wherein certain assets were transferred to BriaPro Therapeutics Corp., resulting in BriaCell retaining a 66.6% ownership in BriaPro. As of December 16, 2024, 44,204,161 common shares of the Company were outstanding.

Document Link: View Document